Epilepsi ile İlişkili Anti-Nöronal Otoantikorlar ve İlişkili Nörolojik Sendromlar

Otoimmünite ve inflamasyon sebebi bilinmeyen epilepsilerin etyolojik faktörleri olarak gösterilebilir. Belli otoimmün hastalıklar ile nöbetler arasında açık bir ilişki olduğu son yıllarda ortaya konulmuştur. Epilepsi hastalarının serumlarında otoantikorların tespit edilmesi bu fikri desteklemektedir. Antikorların çoğu nöronal yüzey moleküllerine karşı oluşur. Diğer otoantikorlar hücre içi antijenleri hedefler. Bu makale, epilepsi ile ilişkili olan başlıca anti-nöronal otoantikorları ve ilişkili nörolojik sendromları özetlemektedir.

Anti-Neuronal Autoantibodies Associated with Epilepsy and Related Neurological Syndromes

Autoimmunity and inflammation can be shown as causative factors of epilepsies of unknown cause. The clear relationship between seizures and certain autoimmune diseases has been revealed in recent years. The detection of autoantibodies in the serum of patients with epilepsy supports this notion. Most of the epilepsy-associated antibodies occur against molecules on the surface of neurons, whereas the remaining autoantibodies target intracellular antigens. In this article, we summarize anti-neuronal autoantibodies associated with epilepsy and associated neurological syndromes.

Kaynakça

Vincent A, Crino PB. Systemic and neurologic autoimmune disorders associated with seizures or epilepsy. Epilepsia 2011;52 Suppl 3:12–7.

Bien CG, Scheffer IE. Autoantibodies and epilepsy. Epilepsia 2011;52 Suppl 3:18–22.

Cojocaru IM, Cojocaru M. Reactions of the immune system in epilepsy. Maedica (Buchar) 2010;5(3):201–6.

Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010;9(8):776–85.

Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011;69(5):892–900.

Hunt DL, Castillo PE. Synaptic plasticity of NMDA receptors: mechanisms and functional implications. Curr Opin Neurobiol 2012;22(3):496–508.

Waxman EA, Lynch DR. N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 2005;11(1):37–49.

Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61(1):25–36.

Irani SR, Vincent A. NMDA receptor antibody encephalitis. Curr Neurol Neurosci Rep 2011;11(3):298–304.

Peery HE, Day GS, Dunn S, Fritzler MJ, Prüss H, De Souza C, et al. Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun Rev 2012;11(12):863–72.

Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12(2):157–65.

Kleinig TJ, Thompson PD, Matar W, Duggins A, Kimber TE, Morris JG, et al. The distinctive movement disorder of ovarian teratoma-associated encephalitis. Mov Disord 2008;23(9):1256–61.

Smith JH, Dhamija R, Moseley BD, Sandroni P, Lucchinetti CF, Lennon VA, et al. N-methyl-D-aspartate receptor autoimmune encephalitis presenting with opsoclonus-myoclonus: treatment response to plasmapheresis. Arch Neurol 2011;68(8):1069–72.

Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10(1):63–74.

Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7(12):1091–8.

Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. Nmethyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010;133(Pt 6):1655–67.

Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009;65(4):424–34.

Lu W, Shi Y, Jackson AC, Bjorgan K, During MJ, Sprengel R, et al. Subunit composition of synaptic AMPA receptors revealed by a single-cell genetic approach. Neuron 2009;62(2):254–68.

Bataller L, Galiano R, García-Escrig M, Martínez B, Sevilla T, Blasco R, et al. Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology 2010;74(3):265–7.

Graus F, Boronat A, Xifró X, Boix M, Svigelj V, García A, et al. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 2010;74(10):857–9.

Wei YC, Liu CH, Lin JJ, Lin KJ, Huang KL, Lee TH, et al. Rapid progression and brain atrophy in anti-AMPA receptor encephalitis. J Neuroimmunol 2013;261(1-2):129–33.

Benarroch EE. GABAB receptors: structure, functions, and clinical implications. Neurology 2012;78(8):578–84.

Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010;9(1):67–76.

Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 2011;76(9):795–800.

Jeffery OJ, Lennon VA, Pittock SJ, Gregory JK, Britton JW, McKeon A. GABAB receptor autoantibody frequency in service serologic evaluation. Neurology 2013;81(10):882–7.

Höftberger R, Titulaer MJ, Sabater L, Dome B, Rózsás A, Hegedus B, et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 2013;81(17):1500–6.

Jarius S, Steinmeyer F, Knobel A, Streitberger K, Hotter B, Horn S, et al. GABAB receptor antibodies in paraneoplastic cerebellar ataxia. J Neuroimmunol 2013;256(1-2):94–6.

Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014;13(3):276–86.

Ohkawa T, Satake S, Yokoi N, Miyazaki Y, Ohshita T, Sobue G, et al. Identification and characterization of GABA(A) receptor autoantibodies in autoimmune encephalitis. J Neurosci 2014;34(24):8151–63.

Macdonald RL, Kang JQ, Gallagher MJ. Mutations in GABAA receptor subunits associated with genetic epilepsies. J Physiol 2010;588(Pt 11):1861–9.

Carvajal-González A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain 2014;137(Pt 8):2178–92.

Baer K, Waldvogel HJ, Faull RL, Rees MI. Localization of glycine receptors in the human forebrain, brainstem, and cervical spinal cord: an immunohistochemical review. Front Mol Neurosci 2009;2:25.

Lynch JW. Molecular structure and function of the glycine receptor chloride channel. Physiol Rev 2004;84(4):1051–95.

Mas N, Saiz A, Leite MI, Waters P, Baron M, Castaño D, et al. Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 2011;82(12):1399–401.

Damásio J, Leite MI, Coutinho E, Waters P, Woodhall M, Santos MA, et al. Progressive encephalomyelitis with rigidity and myoclonus: the first pediatric case with glycine receptor antibodies. JAMA Neurol 2013;70(4):498–501.

McKeon A, Martinez-Hernandez E, Lancaster E, Matsumoto JY, Harvey RJ, McEvoy KM, et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol 2013;70(1):44–50.

Stern WM, Howard R, Chalmers RM, Woodhall MR, Waters P, Vincent A, et al. Glycine receptor antibody mediated Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM): a rare but treatable neurological syndrome. Pract Neurol 2014;14(2):123–7.

Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010;67(4):470–8.

Liimatainen S, Peltola M, Sabater L, Fallah M, Kharazmi E, Haapala AM, et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia 2010;51(5):760–7.

Senties-Madrid H, Vega-Boada F. Paraneoplastic syndromes associated with anti-Hu antibodies. Isr Med Assoc J 2001;3(2):94– 103.

Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associ ated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992;71(2):59–72.

Zuliani L, Graus F, Giometto B, Bien C, Vincent A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry 2012;83(6):638–45.

Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 2010;257(4):509–17.

Graus F, Keime-Guibert F, Reñe R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124(Pt 6):1138–48.

Graus F, Dalmau J. Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol 2007;20(6):732–7.

Bataller L, Kleopa KA, Wu GF, Rossi JE, Rosenfeld MR, Dalmau J. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry 2007;78(4):381–5.

Ekizoglu E, Tuzun E, Woodhall M, Lang B, Jacobson L, Icoz S, et al. Investigation of neuronal autoantibodies in two different focal epilepsy syndromes. Epilepsia 2014;55(3):414–22.

Bien CG. Value of autoantibodies for prediction of treatment response in patients with autoimmune epilepsy: review of the literature and suggestions for clinical management. Epilepsia 2013;54 Suppl 2:48–55.

Kaynak Göster